Physician profile
Michael J Heck
NPI 1154379659
$955.45
in general payments reported to CMS, 2019-2025
12 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $121 · 2021: $126 · 2022: $58.25 · 2023: $184 · 2024: $82.83 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $431.35 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Depuy Synthes Sales INC. | $160.29 | 2020-2021 | |
| Abbvie INC. | $135.96 | 2021-2025 | |
| Daiichi Sankyo INC. | $42.43 | 2024-2025 | Injectafer |
| Ironwood Pharmaceuticals, INC | $33.11 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $31.68 | 2022-2024 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $28.49 | 2023 | Trintellix |
| Edwards Lifesciences Corporation | $26.99 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $20.54 | 2025 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.74 | 2024 | Xifaxan |
| Lilly USA, LLC | $13.79 | 2024 | Zepbound, Jardiance |
| Amgen INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Heck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.